Elunetirom received FDA Fast Track designation as an adjunctive therapy for bipolar depression, with phase 2 AMPLIFY-BD data expected in 2026.
The US Food and Drug Administration (FDA) has granted Fast Track designation to elunetirom (ABX-002) for adjunctive treatment of depressive episodes associated with bipolar I or bipolar II disorder in adults, according to a May 26 announcement from Autobahn Therapeutics.1
“The receipt of Fast Track is an important advancement in our efforts to bring elunetirom to patients suffering from
Elunetirom is an investigational, once-daily oral small molecule prodrug designed to penetrate the central nervous system and activate CNS thyroid hormone receptors. Autobahn is developing the agent as an adjunctive therapy rather than monotherapy for bipolar depression and
The regulatory action comes as elunetirom is being evaluated in AMPLIFY-BD, an ongoing phase 2 trial in adults with bipolar
Key Facts
Bipolar depression remains a major driver of disability in bipolar disorder, with depressive symptoms often accounting for a substantial proportion of illness burden compared with manic or hypomanic episodes. Current guideline-supported treatments include mood stabilizers and selected atypical antipsychotics, with treatment selection shaped by polarity of illness, prior response, comorbidities, suicide risk, metabolic risk, and tolerability.4 In practice, clinicians often balance modest antidepressant effects against concerns about weight gain, sedation, extrapyramidal symptoms, metabolic complications, sexual adverse effects, and the risk of mood destabilization.
Fast Track designation is reserved for investigational drugs intended to treat serious conditions and address unmet medical need. Under FDA policy, the designation can facilitate development through earlier and more frequent agency communication, including discussion of trial design and data needed for approval. It may also permit rolling review of a marketing application if submitted and if the program meets applicable criteria.2
For clinicians, the key question remains whether CNS-directed thyroid hormone receptor agonism can produce clinically meaningful antidepressant effects in bipolar depression without the peripheral thyroid-related safety liabilities that have limited broader use of thyroid hormone strategies. Autobahn stated that elunetirom has shown pharmacokinetic properties, target engagement in brain regions associated with depression, and an acceptable safety and tolerability profile in prior nonclinical and clinical studies; however, the announcement did not provide detailed data, comparator results, or adverse event rates.1
Autobahn is also studying elunetirom as adjunctive treatment for major depressive disorder in the phase 2 AMPLIFY trial, registered as NCT06633016, with topline data expected in the third quarter of 2026.1 Results from both programs will be important for determining whether the drug’s proposed mechanism translates into measurable symptom improvement across depressive disorders or whether effects are confined to selected populations.
Interpretation of the Fast Track designation should remain cautious. The designation may accelerate communication and review pathways, but it is not a surrogate for positive trial outcomes. AMPLIFY-BD will need to define the magnitude of benefit, durability of response, effects on functioning, risk of treatment-emergent mania or hypomania, and thyroid-related or cardiovascular safety signals. Longer-term data would also be needed to clarify whether adjunctive treatment can be maintained safely in a chronic, relapsing illness.
References
